<DOC>
	<DOCNO>NCT01089322</DOCNO>
	<brief_summary>Several study demonstrate efficacy asthma treatment despite correctly diagnose , conveniently prescribe adherent therapeutic , 5 % 10 % asthmatic reach disease control . The aim study measure asthma control , evaluate inflammatory functional characteristic , describe comorbidities aggravate factor phenotype derive characteristic severe asthmatic population follow outpatient university service Sao Paolo , Brazil .</brief_summary>
	<brief_title>Risk Factors Associated Difficult-to-control Asthma</brief_title>
	<detailed_description>Study design : interventional Patients selection : Seventy-four severe asthma patient , age 18 65 year old recruit outpatient clinic Pulmonary Division University SÃ£o Paolo Hospital . Severe asthma define accord GINA . Intervention : 2 week screen period patient treat high inhale corticosteroid dose plus long acting beta 2 agonist 12 week plus oral corticosteroid ( prednisone 40 mg/day ) 2 week . Procedures ( baseline , 2 week 12 week ) : asthma control questionnaire ( ACQ ) , asthma control ( ACT ) test , lung function test , quality life questionnaire ( SGRQ SF-36 ) , exhale nitric oxide ( FeNO ) , induce sputum ( IS ) . After 12 week patient underwent following evaluation : Upper Digestive Endoscopy , Esophageal 24hs pHmetry , High Resolution Chest Tomography , Nasoscope exam , Bronchofibroscopy endobronchial biopsy .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Age 18 65 year Diagnosis moderate severe asthma ( GINA ) least one year Presence airway obstruction reversibility ( document within last 5 year startup study ) Smoking , nonsmoking exsmoking patient &lt; 30 packyears . Need inhaled corticosteroid ( IC ) , &gt; equal 1000mcg Beclomethasone Dipropionate ( DPB ) similar last year plus beta 2 long duration agonist last year . At least one exacerbation need oral corticosteroid last year . Pregnant woman ; Comorbidities may interfere management study ; Patients understand procedure study able provide free clarified consent ; Patients pulmonary disease may interfere evaluation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>SEVERE ASTHMA</keyword>
	<keyword>RISK FACTORS</keyword>
	<keyword>CHARACTERIZATION</keyword>
	<keyword>CLINICAL CONTROL</keyword>
	<keyword>INFLAMMATORY MARKERS</keyword>
	<keyword>SEVERE</keyword>
	<keyword>CONTROL</keyword>
</DOC>